← Back to All US Stocks

Hongchang International Co., Ltd (HCIL) Stock Fundamental Analysis & AI Rating 2026

HCIL OTC Electromedical & Electrotherapeutic Apparatus NV CIK: 0001086303
Recently Updated • Analysis: Apr 11, 2026 • SEC Data: 2025-12-31
Combined AI Rating
SELL
64% Confidence
AGREEMENT
SELL
68% Conf
HOLD
60% Conf

📊 HCIL Key Takeaways

Revenue: $11.3M
Net Margin: 8.8%
Free Cash Flow: $-1.5M
Current Ratio: 0.85x
Debt/Equity: 0.16x
EPS: $0.00
AI Rating: SELL with 68% confidence
Hongchang International Co., Ltd (HCIL) receives a SELL rating with 64% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $11.3M, net profit margin of 8.8%, and return on equity (ROE) of 2.4%, Hongchang International Co., Ltd demonstrates mixed fundamentals in the Healthcare sector. Below is our complete HCIL stock analysis for 2026.

Is Hongchang International Co., Ltd (HCIL) a Good Investment?

Claude

Company demonstrates positive net income ($1.0M) but exhibits critical cash flow deterioration with negative operating cash flow (-$641.3K) and free cash flow (-$1.5M), indicating severe earnings quality concerns. Acute liquidity crisis with current ratio 0.85x and dangerously low cash reserves ($551.8K) against $22.2M liabilities creates existential solvency risk.

ChatGPT

HCIL is profitable with a 10% operating margin, low leverage, and exceptional interest coverage, suggesting manageable solvency risk. However, negative operating cash flow and free cash flow alongside sub-1.0 liquidity ratios and a very small cash balance signal near-term funding pressure and earnings quality concerns. Maintain a neutral stance until cash conversion and liquidity improve.

Why Buy Hongchang International Co., Ltd Stock? HCIL Key Strengths

Claude
  • + Positive net income and acceptable 10% operating margin demonstrate underlying business profitability
  • + Conservative leverage with 0.16x debt-to-equity ratio provides some balance sheet cushion
  • + Minimal debt service burden with 1118x interest coverage ratio
ChatGPT
  • + Positive operating and net profitability
  • + Low debt with extremely high interest coverage
  • + Equity base comfortably exceeds liabilities

HCIL Stock Risks: Hongchang International Co., Ltd Investment Risks

Claude
  • ! Severe cash flow deterioration: negative operating cash flow and negative $1.5M free cash flow indicate earnings are not converting to cash
  • ! Critical liquidity crisis: current ratio 0.85x and quick ratio 0.84x both below 1.0x with only $551.8K cash against $22.2M liabilities
  • ! Extremely poor capital efficiency with ROE of only 2.4% and ROA of 1.5%, suggesting capital is underdeployed
  • ! Small $11.3M revenue base limits financial flexibility and ability to absorb shocks
ChatGPT
  • ! Sub-1.0 current/quick ratios and limited cash
  • ! Negative operating cash flow and free cash flow
  • ! Low ROE/ROA indicating weak capital efficiency

Key Metrics to Watch

Claude
  • * Operating cash flow trajectory and path to positive cash generation
  • * Cash position and liquidity ratios - must return to safe levels above 1.0x
  • * Free cash flow and monthly cash burn rate given precarious cash balance
ChatGPT
  • * Operating cash flow
  • * Current ratio

Hongchang International Co., Ltd (HCIL) Financial Metrics & Key Ratios

Revenue
$11.3M
Net Income
$1.0M
EPS (Diluted)
$0.00
Free Cash Flow
$-1.5M
Total Assets
$65.9M
Cash Position
$551.8K

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

HCIL Profit Margin, ROE & Profitability Analysis

Gross Margin 17.1%
Operating Margin 10.0%
Net Margin 8.8%
ROE 2.4%
ROA 1.5%
FCF Margin -13.2%

HCIL vs Healthcare Sector: How Hongchang International Co., Ltd Compares

How Hongchang International Co., Ltd compares to Healthcare sector averages

Net Margin
HCIL 8.8%
vs
Sector Avg 12.0%
HCIL Sector
ROE
HCIL 2.4%
vs
Sector Avg 15.0%
HCIL Sector
Current Ratio
HCIL 0.8x
vs
Sector Avg 2.0x
HCIL Sector
Debt/Equity
HCIL 0.2x
vs
Sector Avg 0.6x
HCIL Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Hongchang International Co., Ltd Stock Overvalued? HCIL Valuation Analysis 2026

Based on fundamental analysis, Hongchang International Co., Ltd has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
2.4%
Sector avg: 15%
Net Profit Margin
8.8%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.16x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Hongchang International Co., Ltd Balance Sheet: HCIL Debt, Cash & Liquidity

Current Ratio
0.85x
Quick Ratio
0.84x
Debt/Equity
0.16x
Debt/Assets
33.7%
Interest Coverage
1,118.04x
Long-term Debt
$6.9M

HCIL Revenue & Earnings Growth: 5-Year Financial Trend

HCIL 5-year financial data: Year 2020: Revenue $222.7K, Net Income -$488.4K, EPS N/A. Year 2021: Revenue $222.7K, Net Income -$548.4K, EPS N/A. Year 2022: Revenue $96.5K, Net Income -$163.0K, EPS $0.00. Year 2023: Revenue $2.7M, Net Income -$240.0K, EPS $0.00. Year 2024: Revenue $2.9M, Net Income N/A, EPS $0.00.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Hongchang International Co., Ltd's revenue has grown significantly by 1,187% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.00 indicates the company is currently unprofitable.

HCIL Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-13.2%
Free cash flow / Revenue

HCIL Quarterly Earnings & Performance

Quarterly financial performance data for Hongchang International Co., Ltd including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2026 $2.8M $304.3K $0.00
Q2 2026 $2.8M -$44.8K $0.00
Q1 2026 $2.0M -$21.7K $0.00

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Hongchang International Co., Ltd Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$641.3K
Cash generated from operations
Capital Expenditures
$856.9K
Investment in assets
Dividends
None
No dividend program

HCIL SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Hongchang International Co., Ltd (CIK: 0001086303)

📋 Recent SEC Filings

Date Form Document Action
Feb 13, 2026 10-Q ea0275803-10q_hongchang.htm View →
Nov 13, 2025 10-Q ea0264488-10q_hongchang.htm View →
Aug 14, 2025 10-Q ea0252560-10q_hongchang.htm View →
May 13, 2025 8-K ea0241884-8k_hong.htm View →
Apr 30, 2025 8-K ea0240023-8k_hong.htm View →

Frequently Asked Questions about HCIL

What is the AI rating for HCIL?

Hongchang International Co., Ltd (HCIL) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 64% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are HCIL's key strengths?

Claude: Positive net income and acceptable 10% operating margin demonstrate underlying business profitability. Conservative leverage with 0.16x debt-to-equity ratio provides some balance sheet cushion. ChatGPT: Positive operating and net profitability. Low debt with extremely high interest coverage.

What are the risks of investing in HCIL?

Claude: Severe cash flow deterioration: negative operating cash flow and negative $1.5M free cash flow indicate earnings are not converting to cash. Critical liquidity crisis: current ratio 0.85x and quick ratio 0.84x both below 1.0x with only $551.8K cash against $22.2M liabilities. ChatGPT: Sub-1.0 current/quick ratios and limited cash. Negative operating cash flow and free cash flow.

What is HCIL's revenue and growth?

Hongchang International Co., Ltd reported revenue of $11.3M.

Does HCIL pay dividends?

Hongchang International Co., Ltd does not currently pay dividends.

Where can I find HCIL SEC filings?

Official SEC filings for Hongchang International Co., Ltd (CIK: 0001086303) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is HCIL's EPS?

Hongchang International Co., Ltd has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is HCIL a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Hongchang International Co., Ltd has a SELL rating with 64% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is HCIL stock overvalued or undervalued?

Valuation metrics for HCIL: ROE of 2.4% (sector avg: 15%), net margin of 8.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy HCIL stock in 2026?

Our dual AI analysis gives Hongchang International Co., Ltd a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is HCIL's free cash flow?

Hongchang International Co., Ltd's operating cash flow is $-641.3K, with capital expenditures of $856.9K. FCF margin is -13.2%.

How does HCIL compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin 8.8% (avg: 12%), ROE 2.4% (avg: 15%), current ratio 0.85 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 11, 2026 | Data as of: 2025-12-31 | Powered by Claude AI